

| Report to: | Public Board of Directors | Agenda item: | 9 |
|------------------|---------------------------|--------------|---|
| Date of Meeting: | 27 January 2021 | | |

| Title of Report: | Board Assurance Framework 2020/21 |
|-----------------------|--|
| Status: | For Discussion |
| Board Sponsor: | Cara Charles-Barks, Chief Executive |
| Author: | Adewale Kadiri, Head of Corporate Governance |
| Appendices | Appendix 1: BAF 2020/21 v10.7 |

1. Report

The Board Assurance Framework (BAF) is a key mechanism for ensuring that the Board is able to monitor those risks that could prevent the Trust from achieving its objectives.

This is the Board's sixth view of the 2020/21 BAF which is attached at Appendix A. Since the framework was last considered by the Board at its meeting in November 2020, meetings of the Audit and Risk, Clinical Governance and Finance and Performance Committees have been held, and although no changes to ratings of any of the risks were recommended, the following changes and improvements are being made in relation to those discussions:

- Work is being done on the description and presentation of the controls and assurances around each of the risks to enable them to better describe what they do, rather than simply listing individual reports, meetings or groups.
- The Finance and Performance Committee has now taken over responsibility for BAF 4, 5, 7 and 8. It was agreed that reference to the ongoing ED improvement programme would be added to BAF 5.
- More explicit reference to particular pressures of the current wave of COVID have been made in BAF 1, 3 and 4.
- The process of mapping the BAF risks with related risks on the Corporate Register has commenced. The Head of Corporate Governance has now set up regular meetings with the Quality Assurance and Clinical Audit Lead who manages the corporate risk register to ensure that there is a real time consideration as to whether any movements on that register needs to be reflected in the BAF and vice versa.

Preparation of the 2021/22 BAF will commence in February, and during the next round of Committee meetings, members will be asked to consider whether any new risks need to be added, or if existing risks ought to be restated. It should be noted that the Trust's internal auditors have already queried whether a cyber-related risk ought to be included, taking account of the national profile and interest in this area.

A session will be held in March to finalise the new BAF and discuss and agree the Board's risk appetite across the various domains.

2. Recommendations

| Author: Adewale Kadiri, Head of Corporate Governance | Date: 19 November 2020 |
|---|------------------------|
| Document Approved by: Cara Charles-Barks, Chief Executive | Version: 1.0 |
| Agenda Item: 9 | Page 1 of 2 |

The Board of Directors is asked to review the Board Assurance Framework and:

- Note and comment on the inclusion of linked risks on the corporate risk register;
- Confirm the risk descriptions;
- Provide any comment or feedback on the controls, assurances, and suggestions on gaps and actions;
- Provide early commentary on possible new risks for the 2021/22 BAF.

3. | Legal / Regulatory Implications

The Board of Directors is required to have a Board Assurance Framework in place for the year. In addition the Board Assurance Framework is one of the key sources of evidence to support the preparation of the Annual Governance Statement.

4. Risk (Threats or opportunities, link to a risk on the Risk Register, Board Assurance Framework etc)

The Board of Directors requires assurance that the Trust's priority objectives will be delivered, and must have regard to the key risks which may impact on this delivery. The Board Assurance Framework is the mechanism for monitoring the effectiveness of the controls that are in place to manage or mitigate these risks.

5. Resources Implications (Financial / staffing)

The production and maintenance of the Board Assurance Framework is the responsibility of the Head of Corporate Governance in conjunction with the relevant Executive Directors of the Trust.

6. **Equality and Diversity**

No issues have been identified in this report.

7. References to previous reports

This paper should be read in conjunction with the Strategic Framework for Risk Management, and quarterly update reports are presented to the Board.

8. Freedom of Information

Public.

Date: 19 November 2020

Version: 1.0



| BAF | 1 |
|-----|---|
| | |

Strategic objective

- Recognised as a listening organisation, patient centred and compassionate
- Meet the individual needs of patients and carers, through high quality treatment and care throughout the patient journey: putting the patient at the heart of all we do.
- Quality improvement and innovation each and every day

Risk

If the Trust fails to capture or respond to patient experience feedback and learn from complaints, claims, incidents and inquests, it may result in avoidable patient harm, decrease in patient safety and outcomes, and a decrease in patient confidence in the Trust's services, further leading to regulatory intervention and adverse publicity that damage the Trust's reputation and could affect CQC registration.

The COVID-19 pandemic has limited patient choice and detrimentally affected the patient experience. It has also reduced opportunities to gain feedback from which the Trust can learn.

| Trust Values | Making a Difference | Lead Executive(s) | Medical Director and Director of Nursing & |
|---------------------------|---------------------|-----------------------------------|--|
| | | | Midwifery |
| Latest Review Date | 12 January 2021 | Board Monitoring Committee | Clinical Governance Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change si Quar | Relate | ed BAF & C | orporate Risk Register Entries |
|---------------|-------|-------------|------------|-------|-------------------|--------|------------|--------------------------------|
| Initial | 30/04 | 4 | 4 | 16 | | ID | Score | Summary Risk Description |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|--------------------------|------------------|------------------|--|
| | 8 | 12 | 16 | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|---|------------------|
| Participation in local and national patient engagement activity Implementation of divisional driver metrics, using the countermeasure summary to drive actions Complaints and PALS systems and processes including monitoring | Internal assurances: Quarterly patient experience report to Quality Board, CGC and Board of Directors including data on complaints handling, PALS and trend analysis. | |
| themes. | Patient involvement in the incident investigation process. | |



- Duty of Candour policy and processes, compliance against which is monitored
- Internal Audit process.
- Monthly Quality Board meeting.
- Freedom to Speak Up process

Improvement plans following national patient surveys.

Patient Stories at Board of Directors meetings and made available on intranet for staff.

Lead for Claims, Inquests and Risk meets regularly with Divisions to share learning.

Overarching objective to improve patient safety. The focus is on increasing overall incident reporting and reducing the number of incidents resulting in moderate or serious harm.

Using the Friends and Family Test to measure performance against the patient experience goal to be a listening organisation, patient centred and compassionate.

Review of the patient experience Quality Account priorities by the Council of Governors' Quality Working Group, in partnership with patient groups.

Introduction of the Medical Examiner system to provide bereaved families with opportunities to raise concerns and align with the Learning from Deaths framework and Universal Mortality Reviews.

Patient experience concerns raised with and by the Trust's Freedom to Speak Up Guardian.

Patient involvement in key strategic groups such as End of Life Care, Dementia, Outpatients and Mental Health.

Executive 'Go and See Walks'.

External assurances:

Referral to the PHSO and outcomes

Monthly Friends and Family Scores.

Results of annual programme of CQC national patient surveys.



| Council of Governors – feedback from members and the public. |
|---|
| CCG representation on the Serious Incident Panel and involvement in investigation. |
| Healthwatch feedback and commissioned work, and feedback from the county wide Carer Centres |
| Programme of regular CQC liaison meetings and core service liaison meetings |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|--|----------------------------------|--|-------------|----------|
| Hiatus in CCG quality assurance work since the BSW merger | | Director of Nursing and Midwifery to engage with BSW CCG – collaborative working among the 3 local acutes is | Mar 2021 | Ongoing |
| , and the second | | being developed. The DoNM is now a member of the BSW Quality Surveillance Group. The Quality Contract and Schedule is being reviewed. | | |
| | Feedback from friends and family | A new process for obtaining feedback from friends and family is to take effect from 1 July 2020. This will ask questions about patients' overall experience and others that are linked to True North measures – The A3 around being a listening organisation is being reviewed | Feb 2021 | Complete |
| Unable to properly understand patient and carers' experience, especially around those with protected characteristics | | The work of the Patient and Carers' Experience Group is under review as to whether a different approach ought to be taken. The aim is to make the Group more dynamic and representative | Mar 2021 | Ongoing |
| | | Option to run See It My Way sessions virtually is being explored A Volunteer Strategy is under development to be signed off by the People Committee in Jan '21 To develop a Patient Experience Partnership Group | Jan 21 | |
| | | including Healthwatch and other support groups to identify gaps in understanding, e.g. homeless, Polish | Mar 21 | |





| ı | (| í | í |
|---|---|---|---|
| ı | 1 | | |
| ı | 1 | | • |
| | | | |



| DAF Z | |
|-----------|-----------|
| Strategic | objective |

- Be an outstanding place to work where staff can flourish
- Be a flexible and dynamic employer of choice, providing rewarding careers, staff support, clear and open communications and compassionate leadership

Risk

If shortages in the supply of registered nurses, doctors and other healthcare professionals impacts on the Trust's ability to fill vacancies, it will affect the provision of consistently safe and high quality care, workload, staff morale and resilience. This will impact on the Trust's status as an employer of choice in the local area, further reducing the ability to recruit and retain staff, and further impacting on patient care and experience.

Although the Trust has been successful in reducing the current numbers of unfilled vacancies, concerns remain about the sustainability of the measures that have been taken to achieve this.

| Trust Values | Everyone Matters | Lead Executive(s) | Director for People |
|---------------------------|------------------|-----------------------------------|---------------------|
| Latest Review Date | 1 October 2020 | Board Monitoring Committee | People Committee |

| Risk Rating | Date | Consequen ce | Likelihood | Score | Change since last Quarter | Relate | Related BAF & Corporate Risk Register Entries | | |
|-------------|-------|--------------|------------|-------|------------------------------|--------|---|---|--|
| Initial | 30/4 | 4 | 4 | 16 | | ID | Score | Summary Risk Description | |
| Current | 01/09 | 4 | 2 | 8 | | 2075 | | 2075 Risk that patient safety will be affected by inadequate Medical and Nursing staffing within Emergency Department and UTC | |
| Target | | 4 | 2 | 8 | | 2010 | | ICU workforce to manage COVID workload | |
| | | | | | | 2084 | | Increased staff absence due to Covid 19 | |
| | | | | | | 1697 | | 1697 Insufficient Clinical Oncologists due to vacant posts | |
| | | | | | | 1762 | | NICU Medical Staffing | |
| | | | | | | 1870 | | Pharmacy Staffing | |
| | | | | | | 2059 | | Radiographer Night shift staffing levels | |



| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|-------------------------|--------------------------|------------------|-------------------------|--|
| | 8 | 8 | 8 | | |
| | | | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|---|------------------|
| Improving Together Programme – investment in staff. | Internal Assurance | |
| Trust Membership of QUEST | Workforce Reports and risks to Strategic Workforce Committee | |
| Investment in staff engagement and team development N&MW Strategy 2017 - 2020 | Monthly Workforce Metrics Reports to Management Board and Board of Directors | |
| Medical, N&M, AHP and scientific workforce Planning Groups | Stress Audits | |
| - · · · · · · · · · · · · · · · · · · · | EAP monthly reports | |
| N&M Recruitment & Retention Group and action plan | People Committee review and challenge | |
| Ongoing international recruitment programme | Director ward/department 'Go and See Walks' | |
| Trust and Divisional workforce plans | 'Go Engage' quarterly survey results | |
| Talent management and succession planning programme. | Health & wellbeing Activities monitored via H&W steering group | |
| Leadership Strategy Preceptorship Policy for Nurses, Midwives and AHPs | Monthly monitoring of staff survey actions at Strategic Workforce Committee | |
| Health and Wellbeing Strategy | N&M Recruitment & Retention Plan reviewed at monthly N&M Workforce | |
| Values embedded Trust objectives, appraisal process and recruitment | Planning Group | |
| Agency controls and rota support | Analysis of trends emerging from Freedom to Speak Up disclosures | |
| Neutral vendor contract in place for nurse agency (with Bristol Trusts) | | |
| Electronic staffing dashboard | External Assurance | |
| Liectronic staming dashboard | Annual Staff Survey Results | |
| Implementation of Allocate rostering system | Annual Patient Survey Results | |
| HEE CPD funding – every nurse, midwife and AHP receives £1000 and a plan is developed for how this will be used | Friends and Family Test results | |
| | E&Y Well-Led assessment in 2018 | |





| Recruitment and retention of nursing staff is a Breakthrough Objective | |
|--|--|
| Freedom to Speak Up agenda | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|--|---|--|----------|-----|
| No current approved Leadership Strategy | | Leadership Strategy is in development | | |
| | Vacancies in key roles (e.g Associate Director of Organisational and People Development | Post to be advertised in September | Dec 2020 | |
| Resourcing of BSW strategic workforce planner | | Due for recruitment in September | Dec 2020 | |
| Effectiveness of BSW Local Workforce Action Board | | Clear structure and position now in place with scope for further development in the future | Dec 2020 | |
| Effective and responsive rostering system | | Roll out of the Allocate system has been delayed as a result of the COVID-19 pandemic | Mar 2021 | |



BAF 3

Strategic objective

- Continue to place patient safety and quality improvement at the heart of all we do.
- Meet individual needs of patients and carers, through high quality treatment and care throughout the patient journey: putting the patient at the heart of what we do.
- Quality improvement and innovation each and every day.

Risk

If the Trust fails to maintain clinical standards, through inadequate clinical practice or failures of governance, this may result in avoidable patient harm and a deterioration in patient safety and outcomes, failure to comply with regulatory standards, and could lead to regulatory intervention, adverse publicity, reputational damage, and loss of confidence by patients and the local community.

The COVID-19 pandemic has brought about delays in access to diagnoses and pathways, and as a result, long waiting lists, and has led to the introduction of additional IPC guidance from Public Health England. There are operational, quality, regulatory and reputational risks around non-compliance with these.

| Trust Values | Making a Difference | Lead Executive(s) | Medical Director and Director of Nursing & |
|--------------------|---------------------|-----------------------------------|--|
| | | | Midwifery |
| Latest Review Date | 12 January 2021 | Board Monitoring Committee | Clinical Governance Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last Quarter | Relate | Related BAF & Corporate Risk Register Entries | | |
|---------------|-------|-------------|------------|-------|------------------------------|--------|---|--|--|
| Initial | 30/04 | 4 | 5 | 20 | _ | ID | Score | Summary Risk Description | |
| Current | 07/01 | 4 | 4 | 16 | T | 180 | | 180 Infection control – inadequate isolation facilities (tolerated risk) | |
| Target | | 4 | 1 | 4 | | 2035 | | Possible breaches of infection prevention and control guidance | |
| | | | | | | 1995 | | Cleaning in line with national guidance for COVID | |
| Risk Appetite | | | | | | | • | · - | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|-------------------------|--------------------------|------------------|-------------------------|--|
| | 8 | 12 | 16 | | |



| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|--|--|------------------|
| Nursing and Midwifery peer audit programme. Departmental, divisional and corporate group structure to monitor compliance with guidance and standards CQC Insight data. Duty of Candour processes and compliance monitored via Management Board. Bi-monthly Mortality Review Group – the Lead for Claims and Inquests now coordinates a review of mortality data, Learning from Deaths, inquests and complaints in order that the information is held centrally and enables the identification of trends for learning and improving care Deteriorating Patient Steering Group – this is to be subsumed within a wider Patient Safety Committee. This new committee will streamline the work that takes place in relation to falls and pressure ulcers Infection, Prevention and Control metrics presented quarterly to Board of Directors within Quality paper. Patient Safety Driver metrics on divisional scorecard Quarterly patient safety summits are to be held with a view to identifying areas of concern and learning from investigations. This will be driven by the work of the Patient Safety Committee COVID IPC IPC Reference Group decides on review and implementation of national IPC guidance: daily outbreak meetings held and weekly reviews of audits of swabbing data. Review of the IPC BAF | Internal assurances: Reports on elements of Safety and Quality to Management Board, Quality Board, Board of Directors and Clinical Governance Committee. Discussion at Monthly Executive Performance Review meetings with Divisions. Triangulation of Executive 'Go and See Walks' via Executive Huddle Meetings. Self-assessment of the core services against the CQC's domains undertaken. Core service leads in depth review and challenge through divisional performance meetings, Quality Board and by Executive leads (including review of evidence and performance data). Nursing Intensive Support Clinical Review process in place – reporting to Divisional performance meetings. Ward and Outpatient accreditation programme developed aligned to the CQC standards and continuous improvement and monitoring system. Ward staffing reviews now revised and in place. Never events reviewed via CGC Learning from Deaths reviewed quarterly by Board of Directors. Detailed guidance on the use of PPE set out on the Trust intranet External assurances: Regular review of Dr Foster data. Outcome of commissioner visits to clinical areas and reports of the visits. External Agency Visits Feedback from patient experience. | Change |
| | | |



| Outcomes and feedback from bi-monthly meeting of the CCGs' Clinical Outcomes and Quality Assurance Committee which reviews and monitors all elements of the quality contract. |
|---|
| Outcomes of reviews by peers or regulators; eg; CQC IRMER inspection, NHSE review of chemotherapy services, NHSI IP&C review, PH peer review etc. |
| Review of progress in addressing recommendations from 2018 CQC inspection. |
| CQC liaison meetings with core services. |
| Internal Auditor review of CQC action plan given significant assurance Self-assessment completed against NHSE/I IPC BAF |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|-----------------------------|-------------------------------------|---|----------|---------|
| | Consistent use of Improving | Embedding the use of driver and tracker metrics into the | Dec | |
| | Together to help drive | monthly executive performance review meetings with the | 2020 | |
| | improvements in clinical standards | divisions | | |
| Implementation of a Quality | | To be launched in the autumn and overseen by Quality | Sept | Ongoing |
| Strategy | | Board – this is to be merged with the Patient Safety | 2020 | |
| | | Strategy. A separate Nursing and Midwifery Strategy is to | | |
| | | be launched in January 2021. – on target | | |
| | Ability for staff to raise concerns | Monthly meetings with the Freedom to Speak Up | Sept | Ongoing |
| | about poor clinical standards | Guardian to continue – in place | 2020 | |
| | | Steps to be taken to ensure that more junior staff (bands | | |
| | | 2 and 3) are able to raise concerns | | |
| | Medicines Management | The Chief Pharmacist now routinely attends Quality | Dec | |
| | | Board and Management Board. Medicines Management | 2020 | |
| | | is to be reviewed by Internal Audit. | | |
| | Audit of effectiveness of COVID | Audits instigated and being carried out by divisional | Jan | Ongoing |
| | related measures (PPE, social | Heads of Nursing | 2021 | |
| | distancing etc) | | | |





| Implementation of National Patient Safety Strategy | • | Setting up Patient Safety Steering Group Reviewing the model for Patient Safety Specialists | Jan 21 Apr 21 | |
|--|---|---|------------------------|--|
| | | | | |



| BAF 4 Strategic objective | Recognised as a listening organisation, patient centred and compassionate |
|---------------------------|---|
| | If the Trust fails to effectively manage the pressures of the COVID-19 outbreak for both patients and staff directly infected, it will fail to maintain safe levels of care and treatment. The Trust will also not be able to offer urgent clinical care for patients not infected with Coronavirus as capacity and staffing levels will not support safe delivery of care. |
| Risk | There is an ongoing risk to public confidence in accessing healthcare providers which may result in patients not seeking help in an emergency in both primary and secondary care. This may result in patients presenting t the Trust late and with advanced symptoms. |
| | There is also the risk that the Trust will be unable to continue with the wider range of clinical activity, with the result that services are either cancelled or patient safety is compromised and staff morale is affected. |

| Trust Values | Everyone matters | Lead Executive(s) | Chief Operating Officer |
|--------------------|---|-----------------------------------|-----------------------------------|
| | Making a difference | | |
| | Working together | | |
| Latest Review Date | 11 January 2021 | Board Monitoring Committee | Finance and Performance Committee |

| Risk Rating | Date | Impact | Likelihood | Score | Change since last Quarter | Related BAF & Corporate Risk Register Entries | | rporate Risk Register Entries |
|---------------|-------|--------|------------|-------|---------------------------|---|-------|--|
| Initial | 30/04 | 5 | 4 | 20 | | ID | Score | Summary Risk Description |
| Current | 10/11 | 5 | 4 | 20 | T | 2106 | | Increase requirements on ITU in response to COVID-19 surge |
| Target | | 5 | 2 | 10 | | 2037 | | Reduced bed base due to social distancing |
| | | | | | | 2074 | | Risk that patient safety and quality of care will be compromised when treated in an overcrowded ED |
| | | | | | | 1909 | | Flow from Critical Care to Surgery may be reduced over winter |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) |
|--|---------------------|-------------------------|-------------------------|--------------------|
| THE COURT OF THE C | a i () ipi may cam, | 4 (6417 (49 666) | 40 (3011101 200) | a i (barri ba mar) |



| 4.5 | 4.5 | 00 | | |
|-----|-----|----|--|--|
| 15 | 15 | 20 | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|--|---|------------------|
| Following daily and weekly guidance provided by national bodies including Public Health England, Department of Health and NHSI/E Gold, Silver and Bronze Command structure that is responsible for the strategic, tactical and day to day management of the response to the outbreak (in line with Major incident response) Executive team oversight of the response and challenge provided to the actions that are being taken Full Board of Director oversight BSW system response and engagement with regional critical care network Clinical Pathway group supporting COVID and non-COVID activity pathways | BSW triggers for step up/step down Daily tracking of agreed performance metrics Assessment against Project plan to increase capacity within the organisation and the wider community (beds, staff & equipment) Gold action log and risk register Regular bed and resources modelling to ensure capacity and/or resources to support clinical services Specific PPE tracking via Gold to ensure 72+ hour provision in all PPE supply lines. | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances Due | ue Date | L/C |
|---|-------------------|---|---------|-----|
| Ability to accurately forecast national and local modelling impact | | Local modelling of impact and daily monitoring of actual performance BSW modelling The Trust has set its own assumptions | Ongoing | |
| Effective risk management with regard to certain classes of staff including those from a BAME background (see BAF 13) | | All risk assessments of BAME staff have been completed Provision of holistic support from team and divisional level up, including via Occupational Health Shielding staff are once again away from work in line with national guidance | Ongoing | |
| Pressure on resources as a result of restart | | Active consultation with divisions and services in terms of PPE requirement, bed numbers, staffing and social distancing requirements Staffing command now working 7 days a week Reservists are being pulled in to support teams under pressure | Ongoing | |



| The pandemic has significantly limited space at the hospital – beds, clinical space, clinical waiting rooms, diagnostic areas and office space – in order to minimise contact risk and support infection control | Different ways of working are being implemented – virtual working, virtual outpatients and some services moved off-site Plastic screens have been put up to bring more beds back into use Home working is being supported across the Trust where possible Signage to support social distancing efforts has been put up across the site Significant proportion of outpatient clinics are now conducted virtually | Ongoing |
|--|---|---------|
| A significant waiting list backlog has developed – it is estimated that it will take 2 years to fix. The number of patients waiting 52 weeks or more for elective care has risen sharply | Use of independent sector facilities is continuing Phase 3 structure is being revised, with a focus on electives, non-electives and winter planning BSW-wide shared waiting lists are being developed | Ongoing |
| System level response | Creation of Urgent Care Flow Board Encouraging patients to think of 111 first; considering booking arrangements for 'minors' at ED Capital – 'Rapid improvement events' (hackathons) held to identify urgent needs (diagnostics for RUH) and provide funding Shared learning across the region Re-establishment of Clinical Cabinet Escalation triggers in place in the event of a spike in cases SDEC now in place | Ongoing |
| Winter – potential for a combination of flu, COVID and Diarrhoea and vomiting | The response to COVID-19, winter pressures, the impact of D20 and phase 3 recovery are all being run as a single incident. | Ongoing |



| BAF 5 Strategic objective | Review, challenge and support the actions we take to improve our performance against national standards; with regard to equality and diversity, and in response to research, evidence and best practice | | | | |
|------------------------------|---|--|--|--|--|
| Risk | If the Trust fails to meet the NHS Constitutional targets (RTT 18 weeks, diagnostic 6 weeks, A&E 4 hours and cancer waits), patients will experience poor quality of care and potentially adverse outcomes. | | | | |
| | Impact of Covid-19 Incident Response – as a result of the response to wave 1 of the Covid-19 pandemic, routine clinical activity stopped. The Trust is not yet back at full capacity, and this has led to long delays in access to elective work. | | | | |

| Trust Values | Making a Difference | Lead Executive(s) | Chief Operating Officer |
|---------------------------|---------------------|-----------------------------------|-----------------------------------|
| Latest Review Date | 11 January 2021 | Board Monitoring Committee | Finance and Performance Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last Quarter | Relate | d BAF & | Corporate Risk Register Entries |
|---------------|-------|-------------|------------|-------|------------------------------|--------|---------|--|
| Initial | 30/04 | 4 | 5 | 20 | _ | ID | Score | Summary Risk Description |
| Current | 30/09 | 4 | 5 | 20 | 1 | 2065 | | Risk that patients may come to harm as a result of excessive waiting times for Cardiac CT scan |
| Target | | 4 | 3 | 12 | | 2060 | | Risks due to reducing imaging capacity in PAW Ultrasound – COVID-19 |
| | | | | | | 2009 | | 52 week breaches - capacity National Risk |
| | | | | | | 2006 | | Backlog of imaging referrals as a result of reduced imaging capacity due to COVID -19 |
| | | | | | | 1484 | | Failure to meet the national DMO1 diagnostic target at Trust level |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|-------------------------|--------------------------|------------------|-------------------------|--|
| | 16 | 20 | 20 | | |



| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|--|------------------|
| Detailed challenge and support at Management Board Regular oversight from Board of Directors and at Clinical Governance Committee Divisional performance reviews Phase 2 COVID Response Programme Board and sub-group structure Phase 3 trajectories agreed at BSW and regional level | CGC assurance of processes surrounding key risks and issues Detailed operational performance report to Board highlighting progress being made on elective recovery informing Board level debate of key risks and issues Internal audit reports around processes for managing various aspects of activity delivery and reporting Monitoring activity against recovery trajectories on a weekly basis | |
| | External | |
| | NHSI Single Oversight Framework ratingCQC Insights Report | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|---|--|--|----------------------------|---------|
| Ability to maximise site capacity to manage increased demand for elective care – social distancing impact and site layout | | Assessing options of environmental enhancements to increase ward and outpatient waiting room capacity Working with Independent Sector partners to maximise use of IS capacity | July 2020 Q3/4 20/21 | Ongoing |
| | | Operating a high proportion of outpatient clinics virtually | | |
| | Unknown unmet need for healthcare as patients have not accessed primary and secondary care due to the perceived risk of Covid-19 | Liaising with GP colleagues to look at different ways of supporting patient needs and building patient confidence National communication plan Local communication plan | Ongoing | |



| BAF 6 | Be an environmentally sustainable organisation that is fit for the future | | | | | |
|---------------------|--|--|--|--|--|--|
| Strategic objective | Reduce our environmental impact by reducing our carbon emissions and our carbon footprint | | | | | |
| Strategic objective | To become carbon neutral by 2050 in line with the climate change act (2008) | | | | | |
| | To implement and maintain an RUH strategic vision for sustainability | | | | | |
| | As a major organisation in B&NES and (the NHS) being a major contributor to UK carbon emissions, failing to enable an | | | | | |
| | appropriate strategy and outcomes for year on year reduction in the RUH environmental impact and carbon emissions will lead to | | | | | |
| Risk | a failure to meet the 2050 carbon neutral target. It may also result in future regulatory intervention and a decrease in staff and | | | | | |
| | public confidence leading to adverse publicity that damages the Trusts' reputation. | | | | | |
| | The True the terms the beautiful and a second secon | | | | | |
| | The Trust's target is now to become carbon neutral by 2030, which will be more difficult to achieve | | | | | |
| | | | | | | |

| Trust Values | Everyone mattersMaking a differenceWorking together | Lead Executive(s) | Director of Estates and Facilities |
|---------------------------|---|----------------------------|------------------------------------|
| Latest Review Date | 13 January 2021 | Board Monitoring Committee | Non-Clinical Governance Committee |

| Risk Rating | Date | Impact | Likelihood | Score | Change since last Quarter | Related | BAF & Co | rporate Risk Register Entries |
|---------------|-------|--------|------------|-------|---------------------------|---------|----------|-------------------------------|
| Initial | 30/04 | 4 | 3 | 12 | | ID | Score | Summary Risk Description |
| Current | 01/09 | 4 | 4 | 16 | | | | |
| Target | | 4 | 2 | 8 | | | | |
| Risk Appetite | | | | | _ | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|-------------------|------------------|-------------------------|--|
| | 12 | 16 | 16 | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|---|------------------|
| Monthly, quarterly and annual review and reporting on energy and CO2 performance (elec, gas, fuel oil, waste, water) 5 year sustainability plan (2020-2025) in place Carbon reduction trajectory (to 2030) in place | Internal Assurance Monthly E&F Divisional Board receives data on energy and CO2 performance and trend Monthly E&F EPR receives data on energy and CO2 performance and trend | |



- NHS Sustainable Development Unit tool for assessing and auditing our sustainability credentials1 embedded within the Trust's Sustainability Plan Development of behavioural change program with support from
- University of Bath.
- Move to 'green' energy supply contracts by April 2021

- Improving Together program includes carbon reduction (sustainability) as True North
- Regular reporting of sustainability to NCGC and feedback
- Annual update and review of SDAT scoring
- Annual collection and review of measured Scope 1 and Scope 2 emissions² underway
- Financial review/reporting to identify issues or trends to inform better planning.

External Assurance

- Annual ERIC submission to NHSi
- Feedback from patients, governors and visitors on the steps that the Trust is taking to improve its environmental sustainability
- Development of a carbon sequestration analysis to ascertain when the Trust needs to move from carbon reduction to offsetting

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|----------------------------------|---------------------------------------|---|----------|---------|
| Inability to obtain sufficiently | | Commissioning more sub-metering | Apr 2022 | Ongoing |
| detailed measurement of energy | | | | |
| use | | | | |
| Delivery against the 5 year | | Implementation of Sustainable Development Management | Apr 2021 | Ongoing |
| sustainability and carbon | | Plan | | |
| reduction targets | | | | |
| Implementation of behavioural | | | Apr 2021 | Ongoing |
| change programme at divisional | | | | |
| level | | | | |
| Timeliness of move to 'green' | | Government drive to move to 'green' energy supply contracts | Apr 2021 | Ongoing |
| energy supply contracts | | by April 2021 | | |
| | Mechanism for obtaining feedback from | Work being done on Trust website to provide information on | Mar 2021 | |
| | patients, visitors and other external | action being taken | | |

¹ Sustainable Development Assessment Tool – SDAT

² Scope 1 emissions - **Direct Emissions** from the activities of an organisation or under their control. Including fuel combustion on site such as gas boilers, standby generators. Scope 2 emissions - Indirect Emissions from electricity purchased and used by the organisation.



| | parties on the Trust's approach to environmental sustainability | | | |
|---------------------------------|---|---------------------------------|----------|--|
| Moving from carbon reduction to | | Initial scoping work being done | Apr 2023 | |
| carbon offsetting | | | | |



| BAF 7 | Work together with our partners to strengthen our community Work in partnership with organisations and groups to build joined-up holistic patient care for all communities in our healthcare |
|---------------------|---|
| Strategic objective | region, including looking after population health |
| | Share in the responsibilities of leadership in our healthcare economy and region, driving forward innovative and collaborative approaches to deliver healthcare improvements and efficiencies |
| Risk | The Trust fails to deliver its financial target, and this leads to a loss of confidence in the Trust's ability to deliver without a higher level of central control, and could lead to regulatory intervention. Within the health economy, the pressures lead to difficult organisational relationships leading to problems in aligning strategic direction and creating an effective and cohesive health and social care system. |
| | There is a risk that the overall funding envelope for the system is insufficient for the 3 Acute Trusts |

| Trust Values | Everyone Matters | Lead Executive(s) | Director of Finance |
|---------------------------|---|-----------------------------------|-----------------------------------|
| | Working Together | | |
| | Making a Difference | | |
| Latest Review Date | 11 January 2021 | Board Monitoring Committee | Finance and Performance Committee |

| Risk Rating | Date | Consequen ce | Likelihood | Score | Change since last Quarter | Rela | ted BAF & | Corporate Risk Register Entries |
|---------------|-------|--------------|------------|-------|---------------------------|------|-----------|---------------------------------|
| Initial | 30/04 | 4 | 3 | 12 | | ID | Score | Summary Risk Description |
| Current | 02/09 | 4 | 4 | 16 | | | | |
| Target | | 4 | 2 | 8 | | | | |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|-------------------------|--------------------------|------------------|-------------------------|--|
| | 12 | 16 | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|--|--|------------------|
| Strategic Plan | Internal Assurance: | |



| Annual Business/Operational Plan | Monthly Finance and Contract Monitoring Reports to Board of Directors |
|---|---|
| Financial Plan and financial reporting | and Management Board |
| Five Year Financial Strategy in place | Monthly CQUIN Scorecard reports to Management Board and Quality Board |
| STP Financial Recovery Plan | Clinical Commissioning Reference Group. |
| RUH Clinical Commissioning Reference Groups Terms of Reference | CCRG Sub-Group (Elective Demand Management Group) to review |
| Clinical Engagement Group | areas where demand is increasing. |
| CCG Engagement Meetings | Contract Review Board meeting. |
| Stakeholder Engagement Plan | Audit Committee |
| PESTLE and SWOT Analysis | |
| Business Planning Process. | External Assurance: |
| RUH senior staff attendance at Clinical Senate and Clinical Network meetings. | Contracts agreed before the start of the financial year with the local Clinical Commissioning Groups |
| CCG QIPP working group | Dr Foster data re market share |
| Weekly BSW FD meetings | Regular Executive-to-executive communications with BaNES CCG regarding system QIPP delivery |
| Fortnightly Overview and Scrutiny meetings including FDs and COOs | STP engagement. |
| | Contract Review Board |
| | 1:1 between Trust and CCG Executives |
| | Full engagement in Sustainability and Transformation Partnership (STP) by Executives and Chair with monthly scheduled meetings of the STP |
| | Acute Alliance – greater focus on service transformation and it is gaining more traction |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|------------------------------------|-------------------|---|----------|-----|
| The divisions remain in crisis | | More peer review and external assurance required, | Ongoing | |
| management mode, particularly | | including the different organisations within the system | | |
| in relation to capital expenditure | | reviewing each other's plans | | |





| Effectiveness of controls | Greater use of Internal Audit | |
|---------------------------|---|--|
| | More triangulation of risk – to include workforce, operations, finance and safety | |



| BAF 8 Strategic objective | Work in partnership with organisations and groups to build joined-up holistic patient care for all communities in our healthcare region, including looking after population health Share in the responsibilities of leadership in our healthcare economy and region, driving forward innovative and collaborative approaches to deliver healthcare improvements and efficiencies |
|---------------------------|---|
| Risk | Demand for services across the BSW footprint is not matched by supply and/or the system is not adequately funded. The lack of capacity planning across the system, and the lack of community and social care capacity would have a knock on effect on patient flow. |

| Trust Values | Everyone Matters | Lead Executive(s) | Chief Operating Officer |
|---------------------------|---------------------|-----------------------------------|-----------------------------------|
| | Working Together | | |
| | Making a Difference | | |
| Latest Review Date | 2 September 2020 | Board Monitoring Committee | Finance and Performance Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last month | Rela | ted BAF & | Corporate Risk Register Entries |
|---------------|------|-------------|------------|-------|-------------------------|------|-----------|---------------------------------|
| Initial | | 4 | 4 | 16 | | ID | Score | Summary Risk Description |
| Current | | 4 | 3 | 12 | | | | |
| Target | | 3 | 2 | 6 | | | | |
| Risk Appetite | | | | | | | • | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|--------------------------|------------------|-------------------------|--|
| | 12 | 12 | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|--|---|------------------|
| ICS Engagement | System-wide A&E action plan regular review and challenge by NHSI/E | |
| Sharing risk of discharge with commissioners | Wiltshire Health & Care Board meetings (and BaNES equivalents) | |
| Improving Together Programme and use of daily improvement huddle | Emergency Care strategy via the UCCB. | |
| targeting whole hospital response Contracting/partnering with tertiary providers in Bristol and elsewhere | Winter Plan 20/21 supported by Clinical Cabinet – continuation of forum to support emergency care flows | |



| A&E Delivery Board (AEDB) chaired BSW Chief Executive | Improving Together programme and roll out of A3 thinking for |
|---|--|
| Partners in Wiltshire Health & Care | improvement plans and particularly UTC/Minors and ED 4hrs Local scorecards monitoring locally owned metrics connecting to the True |
| Wiltshire Integrated Care Board | North. |
| BaNES Integrated Alliance Board | |
| Wiltshire delivery group – a system partner forum to drive transformation | |
| Business planning of demand and capacity at specialty level | |
| Locally developed performance trajectories against improvement plans | |
| Effective treatment and discharge planning at ward level Strategic goal set as strengthening partnerships across the wider system :True North with breakthrough objective <i>Discharges before Midday</i> | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|-------------------------------------|-------------------|--|----------|-----|
| Insufficient funding to meet demand | | Service transformation | Ongoing | |
| Alignment of priorities across BSW | | Greater engagement and collaborative working | Ongoing | |
| Emergency pressures | | Re-alignment of funding to address gaps in social and community care | Ongoing | |



| BAF 9 Strategic objective | Live our values, so every member of staff knows they matter and are making a difference Share in the responsibilities of leadership in our healthcare economy and region, driving forward innovative and collaborative approaches to deliver healthcare improvements and efficiencies |
|------------------------------|--|
| Risk | If the Trust is unable to maintain and develop leadership that can motivate and bring staff on the organisational development journey, this may lead to disengagement, and inconsistency in the adoption of the Trust's values and culture across the organisation, resulting in reduced staff morale and poorer patient outcomes. |
| | The Trust needs to take specific steps to increase the leadership opportunities for staff with protected characteristics, as illustrated in the Workforce Race and Disability Equality Standards |

| Trust Values | Everyone Matters | Lead Executive(s) | Chief Executive & Director for People |
|---------------------------|---------------------|-----------------------------------|---------------------------------------|
| | Working Together | | |
| | Making a Difference | | |
| Latest Review Date | 9 September 2020 | Board Monitoring Committee | People Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last Quarter | Rela | ted BAF & | Corporate Risk Register Entries |
|---------------|------|-------------|------------|-------|---------------------------|------|-----------|---------------------------------|
| Initial | | 4 | 4 | 16 | | ID | Score | Summary Risk Description |
| Current | | 4 | 3 | 12 | | | | |
| Target | | 4 | 2 | 8 | | | | |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|-------------------|------------------|------------------|--|
| | 12 | 12 | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|---|------------------|
| Talent management and succession planning project | Internal | |
| Engagement with SW Leadership Academy Aspire Programme for 'ready now' directors | Staff survey action plans monitored through Strategic Workforce Committee meetings | |
| Improving Together Programme (executive support workstream, management system training and capability building work stream) | Go Engage survey and team development toolkit | |



| Diversity and Inclusion Strategy - recruitment | Challenge and feedback through TCNC meetings | |
|--|---|--|
| Executive team development programme, extended to Management Board | Monitoring through Improving Together Programme Board | |
| membership | People Committee | |
| Board development programme | External | |
| Organisational values | Well-Led assessment undertaken in 2018 | |
| | | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|--------------------------------|-------------------|--|----------|-----|
| The regional talent management | | The regional talent management programme remains | Dec 2020 | |
| programme has been paused | | paused | | |



| Strategic objective | BAF 11 |
|---------------------|--|
| Risk | If the Trust fails to work effectively as part of the BaNES, Swindon and Wiltshire (BSW) Integrated Care System, the System will not be sustainable and neither the ICS nor the Trust will realise the quality, financial and operational improvement opportunities that would otherwise be available. |
| QI1 | |

| Trust Values | Lead Executive(s) | Chief Executive Officer |
|--------------------|-----------------------------------|-------------------------|
| Latest Review Date | Board Monitoring Committee | Board of Directors |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last Quarter | Rela | ted BAF & | Corporate Risk Register Entries |
|---------------|------|-------------|------------|-------|---------------------------|------|-----------|---------------------------------|
| Initial | | 4 | 3 | 12 | | ID | Score | Summary Risk Description |
| Current | | 5 | 3 | 15 | 1 | | | |
| Target | | 3 | 3 | 9 | | | | |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|-------------------|------------------|-------------------------|--|
| | 12 | 15 | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|--|---|------------------|
| Relationships: | Internal: | |
| Urgent Care Board | Stakeholder mapping and relationship audits | |
| Elective Care Board | STP and Integrated Care Development updates to Board | |
| Acute Hospitals Alliance | Triangulation of STP, strategic and annual plans down to specialty level. | |
| Joint working initiatives e.g. FLOW discharge pathways, MDT care homes pilot, STP Acute Alliance, pathology hub and spoke governance | Finance, Financial Risk and Performance Monitoring Reports to Board of Directors and Management Board | |
| discussions, Urgent Care Centre partnership, Integrated Care Alliance | Contract Review Board | |



Joint forums e.g. STP, Clinical Commissioning Reference Groups, Commissioning College, Wiltshire Health and Care Partnership Board, A&E Delivery Board, Health and Wellbeing Boards, Somerset STP Acute Settings of Care and Clinical Forum, Local Health Economy Communications Group

Associate Medical Director accountability for GP Engagement

System-wide clinical charter and strategy

Integrated Care Alliances with Wiltshire and BaNES

Planning:

Long term integrated planning across health community – STP framework and evolving Integrated Care Partnership and Alliances

Research and Innovation Director role focused on partnerships and new development opportunities

Improving Together infrastructure with a specific True North objective around partnership working, and subject to regular review

Strong QIPP delivery framework and budget management processes

Estates redevelopment programme focused on capacity management

3-5 year strategic planning process and regular review

Population Health Group

RUH membership of the Professional Leadership Network

Monitoring:

Performance and Contract Management Systems

Regular Management Board and Board Meetings

Clinically led, Service Line Management approach

Reporting through Management Board and the Board of Directors around system development

Board of Director Away Day agendas and annual Board review of strategy CoG strategy and outreach groups

External:

STP plan, clinical forum, risk assessment and financial model/monitoring

WH&C performance reports to RUH board

Direct contractual relationships and business plans with local system providers e.g. Virgin Care (e.g. Sexual Health Services); BEMS (e.g. Urgent Care Centre Tender); STP Acute Alliance; Wiltshire Health and Care

NHS long term plan and funding arrangements/ assurances

Memorandum of Understanding around joint waiting list management with GWH and SFT

Active ICS application programme



| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|-----------------------------------|-------------------|--|----------|-----|
| Lack of an appropriate statutory | | Application has been submitted and is being considered | | |
| vehicle to take the ICS forward | | | | |
| Lack of a plan to address the | | Development of the vision and narrative for the ICS. | | |
| gap in the ICS' finances | | Ongoing work on the drivers of deficit | | |
| Sustainability and quality of out | | | | |
| of BSW area care | | | | |



| Strategic objective | BAF 12 |
|---------------------|---|
| | If there is a disorderly EU Exit that does not adequately plan for the needs of the health service, the Trust's ability to operate a full suite of services for patients may be affected, for example: |
| | The availability of key resources, including certain medicines and medical consumables (such as radio-pharmacy isotopes, blood products etc.) may be affected; There may be cost inflation for resources from the EU due to new tariffs or reduced availability (including additional inflation of capital costs); |
| Risk | - Key support services such as radiology, nuclear medicine and pathology may be at risk due to the inability to access parts for equipment manufactured in the EU; |
| | - Wider system risks may occur that increase operational pressure on the Trust e.g. lack of care home staff resulting in care home closures; |
| | Supplies to support the COVID-19 response, including PPE, may be affected; Localised fuel shortages from panic buying may affect staff ability to attend work; |
| | - EU workforce retention and future recruitment of EU citizens may be affected by uncertainties and immigration rule changes; This would result in a reduced level of care for patients and potentially lead to patient harm and possible financial and reputational risk to the Trust. |
| QI1 | |

| Trust Values | | Lead Executive(s) | Chief Operating Officer – SRO: Deputy Chief Executive |
|---------------------------|-------------------|-----------------------------------|---|
| Latest Review Date | 16 September 2020 | Board Monitoring Committee | Audit Committee |

| Risk Rating | Date | Consequence | Likelihood | Score | Change since last Quarter | Relate | d BAF & | Corporate Risk Register Entries |
|---------------|------|-------------|------------|-------|---------------------------|--------|---------|--------------------------------------|
| Initial | | 4 | 4 | 16 | | ID | Score | Summary Risk Description |
| Current | | 4 | 4 | 16 | | 1746 | | Brexit Risks – Linked to procurement |
| Target | | 3 | 3 | 9 | | 1777 | | Cost of medicines post EU exit |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) Q3 (Oct Nov Dec) | | Q4 (Jan Feb Mar) | |
|------------|------------------|------------------------------------|----|------------------|--|
| | 16 | 16 | 16 | | |



| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | Level/ Change |
|---|---|------------------|
| Expected external reporting to regional office on a range of government-led programmes to prepare for end of transition period. | Internal assurances: EU exit Resilience Group, led by Resilience Manager | |
| Regular internal reporting to Management Board led by the Interim COO | Task & Finish Group to recommence meeting 24 September 2020 and 22 Oct 2020. To review changes required from original EU Exit risks following expected publication of DHSC/ NHSEI guidance on the NHS expected impacts. | |
| | Board of Director report to be submitted following national Guidance from October 2020 following initial Management Board discussion once NHS Planning guidance received. | |
| | External assurances: NHSEI have indicated the intention to run system exercises in the week of 12 October 2020. Further assurance requirements are anticipated Review learning from desk top/ virtual exercise scenarios in October 2020. | |
| | National EPRR lead for end of transition planning nominated as Professor Keith Willets. National Briefings will commence in October 2020 following the outcome of political negotiations. | |

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|-----------------|-------------------|--|----------|-----|
| | | | | |



| | BAF 13 |
|---------------------|---|
| Strategic objective | Be an outstanding place to work where staff can flourish |
| Risk | There is clear and emerging evidence of the risk factors that result in higher prevalence and acuity of Covid-19. If the Trust does not undertake risk assessments with staff identified as 'high risk', we will fail in our legal duty to protect the health, safety and welfare of our staff. |
| QI1 | Stan. |

| Trust Values | Everyone Matters | Lead Executive(s) | Director for People |
|---------------------------|------------------|-----------------------------------|---------------------|
| Latest Review Date | | Board Monitoring Committee | People Committee |

| Risk Rating | Date | Impact | Likelihood | Score | Change since last Quarter | Related | BAF & Co | rporate Risk Register Entries |
|---------------|---------|--------|------------|-------|---------------------------|---------|----------|-------------------------------|
| Initial | 26/6/20 | 4 | 3 | 12 | | ID | Score | Summary Risk Description |
| Current | 15/7/20 | 4 | 2 | 8 | | | | |
| Target | 1/8/20 | 4 | 1 | 4 | | | | |
| Risk Appetite | | | | | | | | |

| Risk Score | Q1 (Apr May Jun) | Q2 (Jul Aug Sept) | Q3 (Oct Nov Dec) | Q4 (Jan Feb Mar) | |
|------------|------------------|--------------------------|------------------|-------------------------|--|
| | N/A | 8 | | | |

| Key Controls (what are we doing about the current risk?) | Assurance on Controls (How do we know if the things we are doing are having an impact?) | | |
|---|---|--|--|
| Completion of risk assessment Roll-out of nationally recommended risk assessment document HR Business Partner support for line managers Employee Assistance support for staff who request it, including access to counsellors who specialise in support for BAME staff Staffing Solutions completion of risk assessments with Bank staff identified as being at risk Regular Trust-wide communications across all channels Letters sent directly to the homes of BAME staff members and staff who are shielding about the risk assessment process and support available | Central collation of Covid-19 risk assessments to ensure corporate oversight of completion and quality Daily publication of completion rate at Trust, divisional, speciality and ward / team level Review of progress at Covid-19 Gold Command meetings Daily reporting to NHSI/E All local documentation approved through Covid-19 Workforce Group and Gold Command where appropriate Scrutiny through People Committee | | |



Identification of 'very high risk' staff using Electronic Staff Record to identify priority risk assessments • Engagement in all national and regional discussions about achieving completion of risk assessments to ensure we are up to date and to learn from good practice • All material – risk assessments, letters, other communications – shaped by the BAME Staff Network (Fusion Network) and tested with other staff to ensure documents are easy to understand The use of webforms has been introduced to make completion simpler and ensure that all relevant staff are capturewd Supporting health, safety and welfare of staff Occupational Health support and guidance for staff identified as being at risk, including clear trigger points in risk assessment for OH support • Clear scoring system within risk assessment to ensure appropriate action to be taken Clarity about which parts of the hospital are appropriate working environments, dependent upon risk assessment score • Signposting to Employee Assistance Programme in all material, recognising, for example, that those returning from shielding are likely to feel anxious The People Plan requires that health and wellbeing conversations are held annually with every member of staff

| Gaps in Control | Gaps in Assurance | Actions to Address Gaps in Controls and Assurances | Due Date | L/C |
|---|--|---|----------|-----|
| National guidance on those considered 'at risk' is inconsistent and constantly changing National guidance on data requirements is inconsistent and constantly changing | As at September 2020 92.2% of BAME risk assessments and 56.8% of other 'high risk' risk assessments completed | Broaden the communication to raise awareness of those considered to be 'at risk' in line with changing guidance Broaden the monitoring and incorporate into daily publication of completion rates Further HR Business Partner engagement with line managers | 1/8/20 | |

APPENDIX A: RISK GRADING CRITERIA

Every risk recorded within the Trust's risk registers is assigned a rating, which is derived from an assessment of its Consequence (the scale of impact on objectives if the risk event occurs) and its Likelihood (the probability that the risk event will occur). The risk grading criteria summarised below provide the basis for all risk assessments recorded within the Trust's risk registers, at strategic, operational and project level.

| | Consequence score (severity levels) and examples of descriptors | | | | |
|--|---|---|--|---|---|
| | 1 | 2 | 3 | 4 | 5 |
| Domains | Negligible | Minor | Moderate | Major | Catastrophic |
| Impact on the safety of patients, staff or public (physical or psychological harm) | Minimal injury requiring no/minimal intervention or treatment. No time off work | Minor injury or illness, requiring minor intervention Requiring time off work for >3 days Increase in length of hospital stay by 1-3 days | There is a risk that other providers could innovate more quickly and deliver more services which add to the cost pressures in the system leading to a reduction in funding available for RUH services without reduction in expenditure. Moderate injury requiring professional intervention Requiring time off work for 4-14 days Increase in length of hospital stay by 4-15 days RIDDOR or other agency reportable incident An event which impacts on a small number of patients | Major injury leading to long-term incapacity/ disability Requiring time off work for >14 days Increase in length of hospital stay by >15 days Mismanagement of patient care with long-term effects | Incident leading to death Multiple permanent injuries or irreversible health effects An event which impacts on a large number of patients |
| Quality/ complaints/ audit | Peripheral element of treatment or service suboptimal Informal complaint or inquiry | Overall treatment or service suboptimal Formal complaint (stage 1) Local resolution Single failure to meet internal standards Minor implications for patient safety if unresolved Reduced performance rating if unresolved | Treatment or service has significantly reduced effectiveness Formal complaint (stage 2) complaint Local resolution (with potential to go to independent review) Repeated failure to meet internal standards Major patient safety implications if findings are not acted on | Non-compliance with national standards with significant risk to patients if unresolved Multiple complaints/ independent review Low performance rating Critical report | Totally unacceptable level or quality of treatment or service Gross failure of patient safety if findings not acted on Inquest or ombudsman inquiry Gross failure to meet national standards |

| | 1 | 2 | 3 | 4 | 5 |
|---|--|--|--|--|--|
| Domains | Negligible | Minor | Moderate | Major | Catastrophic |
| Human resources/ organisational development/ staffing/ competence | Short-term low staffing level that temporarily reduces service quality (< 1 day) | Low staffing level that reduces the service quality | Late delivery of key objective/ service due to lack of staff Unsafe staffing level or competence (>1 day) Low staff morale Poor staff attendance for mandatory/key training | Uncertain delivery of key objective or service due to lack of staff Unsafe staffing level or competence (>5 days) Loss of key staff Very low staff morale No staff attending | Non-delivery of key objective or service due to lack of staff Ongoing unsafe staffing levels or competence Loss of several key staff No staff attending mandatory training /key training on an |
| Statutory duty/ inspections | No or minimal impact or breech of guidance/ statutory duty | Breach of statutory legislation Reduced performance rating | Single breech in statutory duty Challenging external recommendation or | mandatory/ key training Enforcement action Multiple breeches in statutory duty | ongoing basis Multiple breeches in statutory duty Prosecution |
| | | if unresolved | improvement notice | Improvement notices Low performance rating Critical report | Complete systems change required Zero performance rating Severely critical report |
| Adverse publicity/ reputation | Rumours Potential for public concern | Local media coverage – short-term reduction in public confidence Elements of public expectation not being met | Local media coverage – long-term reduction in public confidence | National media coverage with <3 days service well below reasonable public expectation | National media coverage with >3 days service well below reasonable public expectation. MP concerned (questions in the House) Total loss of public confidence |
| Business objectives/ projects | Insignificant cost increase/ schedule slippage | <5 per cent over project budget Schedule slippage | 5–10 per cent over project budget Schedule slippage | 10–25 per cent over project budget Schedule slippage Key objectives not met | Incident leading >25 per cent over project budget Schedule slippage Key objectives not met |
| Finance including claims | Small loss Risk of claim remote | Loss of 0.1–0.25 per cent of budget Claim less than £10,000 | Loss of 0.25–0.5 per cent of budget Claim(s) between £10,000 and £100,000 | Uncertain delivery of key objective/Loss of 0.5–1.0 per cent of budget Claim(s) between £100,000 and £1 million Purchasers failing to pay on time | Non-delivery of key objective/ Loss of >1 per cent of budget Failure to meet specification/ slippage Loss of contract / payment by results Claim(s) >£1 million |
| Service/business interruption Environmental impact | Loss or interruption of >1 hour Minimal or no | Loss/interruption of >8 hours Minor impact on | Loss/interruption of >1 day Moderate impact on | Loss/interruption of >1 week Major impact on | Permanent loss of service or facility Catastrophic impact |

Likelihood Score

The Likelihood Score is calculated by determining how likely the risk is to happen according to the following guide. Scores range from 1 for rare to 5 for almost certain.

| Score | Descriptor | Description | | | |
|-------|----------------|---|--|--|--|
| 1 | Rare | Extremely unlikely to happen/recur – may occur only in exceptional circumstances – has never happened before and don't think it will happen (again) | | | |
| 2 | Unlikely | Unlikely to occur/reoccur but possible. Rarely occurred before, less than once per year. Could happen at some time | | | |
| 3 | Possible | May occur/reoccur. But not definitely. Happened before but only occasionally - once or twice a year | | | |
| 4 | Likely | Will probably occur/reoccur. Has happened before but not regularly – several times a month. Will occur at some time. | | | |
| 5 | Almost Certain | Continuous exposure to risk. Has happened before regularly and frequently — is expected to happen in most circumstances. Occurs on a daily basis | | | |

The **Risk Score** is determined by the Consequence (Severity) x Likelihood.

| | Consequence | | | | |
|-----------------------|--------------------|------------|---------------|------------|-------------------|
| Likelihood | 1 Insignificant | 2 Minor | 3 Moderate | 4 Major | 5 Catastrophic |
| 5 – Almost Certain | 5 | 10 | 15 | 20 | 25 |
| 4 – Likely | 4 | 8 | 12 | 16 | 20 |
| 3 – Possible | 3 | 6 | 9 | 12 | 15 |
| 2 – Unlikely | 2 | 4 | 6 | 8 | 10 |
| 1 – Rare | 1 | 2 | 3 | 4 | 5 |